Comparative Pharmacology
Head-to-head clinical analysis: MIDOL versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDOL versus PARAFON FORTE DSC.
MIDOL vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midol is a combination product containing acetaminophen (analgesic/antipyretic via COX inhibition in CNS), caffeine (adenosine receptor antagonist), and pyrilamine (H1 antihistamine). The primary mechanism for dysmenorrhea is prostaglandin synthesis inhibition by acetaminophen.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
Acetaminophen 500 mg, PAM Bromide 15 mg, Pyrilamine Maleate 15 mg: 2 tablets orally every 4-6 hours as needed for dysmenorrhea; maximum 10 tablets per day.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Clinical Note
moderateIopamidol + Metformin
"The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin."
Acetaminophen: 2-3 hours in adults; prolonged to 4-6 hours in neonates or hepatic impairment. Caffeine: 3-6 hours; prolonged in pregnancy or liver disease.
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal: >90% as acetaminophen glucuronide and sulfate conjugates; unchanged drug <5%. Biliary/fecal: <5%.
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Analgesic Combination
Muscle Relaxant/Analgesic Combination